The new drug Litfulo (ritlecitinib) has reached the Canadian market, while baricitinib (Olumiant) is now approved for alopecia areata and in a new higher-strength tablet.
The health insurance board, known as the RAMQ, says it learned of the decision this morning and will immediately start taking steps to implement the change.
Provincial Health Minister Adrian Dix says the nursing ratios will be a first for Canada, and no other jurisdiction in the world has a minimum ratio that applies at all times.
